BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 16556037)

  • 1. Anagrelide for control of thrombocytosis due to myeloproliferative disorders.
    Harrison CN
    Future Oncol; 2005 Oct; 1(5):609-18. PubMed ID: 16556037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile.
    Steurer M; Gastl G; Jedrzejczak WW; Pytlik R; Lin W; Schlögl E; Gisslinger H
    Cancer; 2004 Nov; 101(10):2239-46. PubMed ID: 15476273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New drugs in essential thrombocythemia and polycythemia vera.
    Tefferi A; Elliott MA; Solberg LA; Silverstein MN
    Blood Rev; 1997 Mar; 11(1):1-7. PubMed ID: 9218101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders.
    Birgegård G; Björkholm M; Kutti J; Lärfars G; Löfvenberg E; Markevärn B; Merup M; Palmblad J; Mauritzson N; Westin J; Samuelsson J
    Haematologica; 2004 May; 89(5):520-7. PubMed ID: 15136214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders.
    Fruchtman SM; Petitt RM; Gilbert HS; Fiddler G; Lyne A;
    Leuk Res; 2005 May; 29(5):481-91. PubMed ID: 15755500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anagrelide: a new drug for treating thrombocytosis.
    Silverstein MN; Petitt RM; Solberg LA; Fleming JS; Knight RC; Schacter LP
    N Engl J Med; 1988 May; 318(20):1292-4. PubMed ID: 3362187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Anagrelide-induced changes of megakaryopoiesis during therapy of chronic myeloproliferative disorders with thrombocythemia].
    Thiele J; Kvasnicka HM; Schmitt-Gräff A
    Pathologe; 2002 Nov; 23(6):426-32. PubMed ID: 12436295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders.
    Petitt RM; Silverstein MN; Petrone ME
    Semin Hematol; 1997 Jan; 34(1):51-4. PubMed ID: 9025162
    [No Abstract]   [Full Text] [Related]  

  • 9. [Anagrelide in the treatment of essential thrombocythemia (ET) and other myeloproliferative disorders with thrombocythemia based on data from patient register in the CR].
    Penka M; Doubek M; Schwarz J; Pytlík R; Dulícek P; Kissová J; Hlusí A; Vozobulová V; Cerná O; Brychtová Y; Szotkowski T; Volková Z; Seghetová J; Schutzová M; Hadacová I; Hochová I; Voglová J; Siroký O; Belada D; Lhot'anová T; Bubeník B; Vránová M; Micaníková M; Dusek L
    Vnitr Lek; 2006 May; 52(5):498-503. PubMed ID: 16771099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Chronic myeloproliferative diseases].
    Sréter L
    Orv Hetil; 1998 Jul; 139(30):1779-83. PubMed ID: 9718944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of side effects of BCR/ABL-negative chronic myeloproliferative neoplasm therapies. Focus on anagrelide.
    Antelo ML; de Las Heras N; Gonzalez Porras JR; Kerguelen A; Raya JM
    Expert Rev Hematol; 2015 Dec; 8(6):819-35. PubMed ID: 26368319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anagrelide-induced bone marrow changes during therapy of chronic myeloproliferative disorders with thrombocytosis. an immunohistochemical and morphometric study of sequential trephine biopsies.
    Thiele J; Kvasnicka HM; Fuchs N; Brunnbauer K; Volkwein N; Schmitt-Graeff A
    Haematologica; 2003 Oct; 88(10):1130-8. PubMed ID: 14555309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anagrelide: 20 years later.
    Emadi A; Spivak JL
    Expert Rev Anticancer Ther; 2009 Jan; 9(1):37-50. PubMed ID: 19105705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The results of patients with essentials thrombocythemia and other myeloproliferation-related thrombocythemia--a report of patients treated with Thromboreductin].
    Penka M; Schwarz J; Pavlík T; Indrák K; Doubek M; Dulícek P; Pospísilová D; Kissová J; Jonásová A; Jelínková P; Hlusí A; Schutzová M; Cerná O; Brychtová Y; Nováková L; Korístek Z; Segethová J; Vozobulová V; Hadacová I; Hochová I; Voglová J; Walterová L; Bodzásová C; Dusek L
    Vnitr Lek; 2009 Nov; 55(11):I-XII. PubMed ID: 20017445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The effectiveness of anagrelide treatment in patients with Ph negative myeloproliferative diseases: influence on the incidence of thrombosis in the data from the Registry of patients with essential thrombocythemia and thrombocythemia associated with other myeloproliferative diseases treated with Thromboreductin® to the end of 2012].
    Penka M; Schwarz J; Ovesná P; Cervinek L; Dulíček P; Pospíšilová D; Kissová J; Pavlík T;
    Vnitr Lek; 2013 Jun; 59(6):516-31. PubMed ID: 23808749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment.
    Hultdin M; Sundström G; Wahlin A; Lundström B; Samuelsson J; Birgegård G; Engström-Laurent A
    Med Oncol; 2007; 24(1):63-70. PubMed ID: 17673813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anagrelide in control of myeloproliferative thrombocythemia: long-term experiences in 6 patients].
    Burkhard R; Adam H; Widmer L; Honegger HP
    Schweiz Med Wochenschr; 1998 Nov; 128(46):1808-12. PubMed ID: 9857387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemia.
    Silver RT
    Leukemia; 2005 Jan; 19(1):39-43. PubMed ID: 15510207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders.
    Balduini CL; Bertolino G; Noris P; Ascari E
    Haematologica; 1992; 77(1):40-3. PubMed ID: 1398280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The use of anagrelide to treat thrombocytosis in connection with the chronic myeloproliferative disease].
    Jantunen E; Penttilä K; Kuittinen T; Nousiainen T
    Duodecim; 2006; 122(4):453-7. PubMed ID: 16623100
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.